Provide a genomic-based, comprehensive, individualized risk assessment for early-stage cancers in specific settings.
Inform treatment options for those facing the challenges of advanced-stage cancer.
Understand how genomic testing can help to guide your individualized treatment options.
Accurately identify patients resistant to AR-targeted therapies with an easy-to-follow report. The results presented help facilitate conversations about treatment planning with your mCRPC patients.
You are now leaving this site. Any third party link you select from this site may take you to a website that is not affiliated with Exact Sciences.